Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q1 2026 · 10-Q
Revenue$10.84M$10.84M+37,272.4% vs Q1 2025 Net Income-$18.44M-$18.44MN/M vs Q1 2025 EPS Diluted-$0.75-$0.75N/M vs Q1 2025 Operating Income-$9,075,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
Free Cash Flowderived-$11,955,000N/M Margins · derivedOperating margin-83.7%+76164.5 pt vs Q1 2025
Net margin-170.2%+70743.6 pt vs Q1 2025
ended Mar 31, 2026 · filed May 5, 2026 · 35 d after period end